Development and External Validation of the Hidradenitis Suppurativa Cutaneous Abscess Prediction Score-2 (HSCAPS-2): A Clinical Decision Support Tool for Diagnosis of Hidradenitis Suppurativa over Cutaneous Abscess.

Introduction: Patients with hidradenitis suppurativa (HS) experience a 10-year diagnosis delay, on average. Accordingly, time to diagnosis represents one of the greatest unmet needs in HS, which to date has not been adequately addressed. A general lack of awareness about HS in the medical community and a notable heterogeneity in clinical presentation, which is most often confused with cutaneous abscess (CA), forms the basis of poor disease recognition and diagnosis delay.

Examining the Impact of a Brief Compassion Focused Intervention on Everyday Experiences of Compassion in Autistic Adults Through Psychophysiology and Experience Sampling.

Autistic adults experience greater rates of anxiety and depression compared to the general population. Compassion-focused therapy interventions, aimed at promoting self-compassion capabilities, have shown efficacy in improving mental health outcomes in autistic and non-autistic samples suffering from self-criticism that contribute to difficulties in emotion regulation. We explored the experiences of autistic adults during a brief one-week online self-compassion exercise to evaluate it's feasibility and acceptability through self-report, experience sampling, and parasympathetic activity measured via HRV.

Development of CGS-15943 Adjunctives for the Disruption of Plasmid Maintenance in Multidrug Resistant .

Carbapenemase producing (CPEs) represent a group of multidrug resistant pathogens for which few, if any, therapeutics options remain available. CPEs generally harbor plasmids that encode resistance to last resort carbapenems and many other antibiotics. We previously performed a high throughput screen to identify compounds that can disrupt the maintenance and replication of resistance conferring plasmids through use of a synthetic screening plasmid introduced into K-12 cells.

North American Clinical Practice Guidelines for the Medical Management of Hidradenitis Suppurativa in Special Patient Populations.

Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist.

Objective: To provide evidence-based consensus recommendations for patients with HS in seven special patient populations: i) pregnancy, ii) breastfeeding, iii) pediatrics, iv) malignancy, v) tuberculosis infection, vi) hepatitis B or C infection, and vii) HIV disease.

Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.

Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no FDA approved therapies for early stage HS. Topical JAnus Kinase inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signaling in HS lesions and the recent success of systemic JAKi for moderate to severe HS.

Objectives: This is a pilot, single-site, open-label, prospective 24-week clinical trial with topical ruxolitinib (NCT04414514).